A supplement brand or formulator evaluating a probiotic supplier will usually be shown research. The research is often real, peer-reviewed and genuinely impressive — and it's also, more often than buyers realise, about a strain the supplier isn't actually selling them. Understanding the difference is the single most useful piece of due diligence a buyer can do in this category.
Species Is Not Strain
"Lactobacillus rhamnosus" is a species. "Lactobacillus rhamnosus GG" is a specific strain of that species, with its own genome, its own studies, and its own track record. A different L. rhamnosus strain — genetically distinct, never tested in the cited trials — can be sold under the same species name with the same research pasted onto the datasheet. Nothing about that is necessarily dishonest, but it is a meaningfully different claim than it looks like at first glance.
Our own EmerrBiome strain spotlights are written to keep this distinction visible rather than blur it. A meta-analysis of 19 randomised controlled trials found L. rhamnosus reduced acute diarrhoea duration in children by roughly 24 hours on average — but that evidence is specific to the widely studied "LGG" strain, not the species generally (Li et al., World J Gastroenterol, 2019). A landmark trial found L. plantarum reduced IBS abdominal pain frequency by 52% versus 14% on placebo — specific to strain 299v (Ducrotté et al., World J Gastroenterol, 2012). Neither finding transfers automatically to every strain that shares the species name.
Even Within One Species, Evidence Quality Varies
Bacillus coagulans is a good example of how uneven the picture can be even inside a single, well-regarded species. A meta-analysis of 7 randomised trials found significantly reduced IBS symptom severity — but the evidence spans four distinct named commercial strains, not a generic claim about B. coagulans as a species (AbdelQadir et al., Gastroenterol Endosc, 2024). If a supplier can't tell you which of those strains theirs actually is, the citation is doing more work than the product can support.
Genuinely Mixed Results Are Worth More Than They Look
The most trustworthy sign in probiotic research is often a study that doesn't universally flatter the product. Our EmerrThrive Rumen page cites a dairy-cattle trial where an active yeast additive significantly improved rumen pH stability and fermentation pattern — but found no significant difference in milk yield, intake or feed efficiency versus untreated cows (Plowman et al., Animals, 2026). That's a real, useful benefit and a real limitation, stated in the same breath. A supplier willing to show you the limitation alongside the benefit is usually a more reliable read than one showing only the flattering half.
Four Questions Worth Asking Any Supplier
- Which strain, not just species, is actually in the product — and is that the strain in the cited study, or a different isolate of the same species?
- Does the study population and dose match your intended use — the same organism can behave differently by dose, delivery format and target species.
- What did the study find that didn't work, not only what it found that did?
- Has the supplier's own strain been independently tested, or is the citation borrowed from a different strain of the same species?
Every product page on this site is written to answer those four questions honestly, including where the evidence is thin, mixed, or doesn't yet apply to EmerrBio's own strain. If you're evaluating a manufacturing partner, that's a reasonable bar to hold any supplier to — including us.